Nowak Jonathan A, Hornick Jason L
Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Surg Pathol Clin. 2016 Sep;9(3):427-39. doi: 10.1016/j.path.2016.04.007.
Molecular testing in colorectal cancer helps to address multiple clinical needs. Evaluating the mismatch repair pathway status is the most common use for molecular diagnostics and this testing provides prognostic information, guides therapeutic decisions and helps identify Lynch syndrome patients. For patients with metastatic colorectal cancer, testing for activating mutations in downstream components of the EGFR signaling pathway can identify patients who will benefit from anti-EGFR therapy. Emerging molecular tests for colorectal cancer will help further refine patient selection for targeted therapies and may provide new options for monitoring disease recurrence and the development of treatment resistance.
结直肠癌的分子检测有助于满足多种临床需求。评估错配修复通路状态是分子诊断最常见的用途，这种检测可提供预后信息、指导治疗决策并有助于识别林奇综合征患者。对于转移性结直肠癌患者，检测表皮生长因子受体（EGFR）信号通路下游成分的激活突变可识别出能从抗EGFR治疗中获益的患者。结直肠癌新兴的分子检测将有助于进一步优化靶向治疗的患者选择，并可能为监测疾病复发和治疗耐药性的发展提供新的选择。
